肺动脉高压药物治疗的新认识

随着肺动脉高压（PAH）发病机制的深入研究，对PAH的治疗认识也随着不断提高、更新。单从药物治疗而言，从传统的只重视扩张血管降低肺动脉压为目标，到目前重点放在调节收缩血管因子和舒张血管因子上，使其保持生理平衡是治疗PAH的基本措施。但使用血栓素阻断剂、前列环素类似物、内皮素受体阻断剂、一氧化氮、磷酸二酯酶－5抑制剂等在临床应用后都存在着不同程度的限制因素，如疗效不理想、长期使用不良反应大、价格昂贵等。最近研究发现他汀类药物能克服上述限制因素，且能有效减轻甚至逆转PAH和肺血管重构。

New recognition of drug therapy for pulmonary hypertension

With further investigation in pathogenesis of pulmonary hypertension(PAH) ,the treatment recognition to PAH keeps renewing.As far as drug therapy,orthodox therapy put emphasis on diatating blood vessel and decrease pulmonary artery pressure,while present therapy put emphasis on regulating blood vessel dilatation factors and relaxing factors,and to keep the factors in equibrium is basic measure to treat PAH.However,thromboxane inhibitor,prostacyclin analog,endothelin receptor blocking agents,nitric oxide(NO) ,phosphodiesterase-5 inhibitor etc,they all had different limiting factors such as poor treatment outcome,bad side effects in long term use and high price etc.Lately studies found that statins can conquer these limiting factors,abate and even reverse PAH and pulmonary vascular remodeling.